A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis

Trial Profile

A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Acronyms POMINC
  • Most Recent Events

    • 25 Jun 2017 Results (n=38) from cohort 1 of the study, presented at the 22nd Congress of the European Haematology Association.
    • 06 Dec 2016 Updated results (n=37) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Nov 2016 According to Incyte Corporation media release, data will be presented at 58th Annual American Society of Hematology (ASH) meeting 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top